{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:47:39Z","timestamp":1791229659375,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"am","delay-in-days":430,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1053\/j.seminhematol.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T16:18:22Z","timestamp":1704557902000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Vaccinations in patients with chronic lymphocytic leukemia"],"prefix":"10.1053","volume":"61","author":[{"given":"Elizabeth R.","family":"Francis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Ostos","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8498-4729","authenticated-orcid":false,"given":"Clare","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"Hamblin","year":"2008","journal-title":"British Medical Bulletin"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.003_bib0002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood."},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0003","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","article-title":"Immune defects in patients with chronic lymphocytic leukemia","volume":"55","author":"Ravandi","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.01.003_bib0004","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/1097-0142(19880115)61:2<279::AID-CNCR2820610215>3.0.CO;2-4","article-title":"Serum immunoglobulins in B-chronic lymphocytic leukemia.Natural history and prognostic significance","volume":"61","author":"Rozman","year":"1988","journal-title":"Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ejh.12290","article-title":"Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group","volume":"93","author":"Shvidel","year":"2014","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.003_bib0007","first-page":"440","article-title":"Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia","volume":"12","author":"Whitaker","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2024.01.003_bib0008","series-title":"Infectious complications in cancer patients [Internet]","first-page":"319","article-title":"Infectious complications in cancer patients [Internet]","author":"Morrison","year":"2014"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.003_bib0009","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3390\/ijms21051825","article-title":"Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions","volume":"21","author":"Arruga","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/asheducation-2007.1.332","article-title":"Management of infectious complications in patients with chronic lymphocytic leukemia","volume":"2007","author":"Morrison","year":"2007","journal-title":"Hematology"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.003_bib0011","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","article-title":"Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis","volume":"9","author":"Morrison","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0012","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.003_bib0013","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/1042819031000063408","article-title":"Vaccination against infections in chronic lymphocytic leukemia","volume":"44","author":"Sinisalo","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.003_bib0014","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4065\/75.10.1039","article-title":"Infection and immunity in chronic lymphocytic leukemia","volume":"75","author":"Tsiodras","year":"2000","journal-title":"Mayo Clinic Proceed"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.003_bib0015","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/cncr.11736","article-title":"Pulmonary complications in chronic lymphocytic leukemia","volume":"98","author":"Ahmed","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.003_bib0016","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Reviews"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.003_bib0017","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.vaccine.2021.01.001","article-title":"The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)","volume":"39","author":"Whitaker","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0018","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","article-title":"Serum immunoglobulins and risk of infection: how low can you go?","volume":"39","author":"Furst","year":"2009","journal-title":"Semin Arthritis Rheumatism"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.htct.2023.05.006","article-title":"Infections in patients with chronic lymphocytic leukemia","volume":"45","author":"Guarana","year":"2023","journal-title":"Hematolo Trans Cell Ther"},{"key":"10.1053\/j.seminhematol.2024.01.003_bib0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijid.2013.10.020","article-title":"Immunoglobulin deficiency in patients with Streptococcus pneumoniae or Haemophilus influenzae invasive infections","volume":"19","author":"Martinot","year":"2014","journal-title":"Int J Infect Dis"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.003_bib0021","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0022","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF00368891","article-title":"Epidemiology of influenza A virus infection in patients with acute or chronic leukemia","volume":"3","author":"Elting","year":"1995","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.003_bib0023","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(09)70175-6","article-title":"Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses","volume":"9","author":"Kunisaki","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0024","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/10428194.2017.1347931","article-title":"Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies","volume":"59","author":"Williams","year":"2018","journal-title":"Leukemia Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.003_bib0025","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1086\/513648","article-title":"Influenza among hospitalized adults with leukemia","volume":"24","author":"Yousuf","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0026","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0002-9343(97)00003-X","article-title":"Respiratory Viral Infections in Immunocompetent and Immunocompromised Persons","volume":"102","author":"Couch","year":"1997","journal-title":"Am J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.003_bib0028","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0029","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CLM.2006.n.049","article-title":"Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab","volume":"7","author":"O'Brien","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.003_bib0030","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.3109\/10428194.2012.755178","article-title":"Viral infections and their management in patients with chronic lymphocytic leukemia","volume":"54","author":"Melchardt","year":"2013","journal-title":"Leukemia Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0031","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/ehm.10.77","article-title":"Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab","volume":"4","author":"Vallejo","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"10.1053\/j.seminhematol.2024.01.003_bib0032","series-title":"Immunobiology [Internet]","article-title":"The immune system in health and disease","author":"Janeway","year":"2001"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0033","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0034","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.it.2020.12.002","article-title":"Complement factors in COVID-19 therapeutics and vaccines","volume":"42","author":"Kurtovic","year":"2021","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0035","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2008.1.450","article-title":"Disease-specific complications of chronic lymphocytic leukemia","volume":"2008","author":"Dearden","year":"2008","journal-title":"Hematology"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0036","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/bjh.15918","article-title":"Chronic lymphocytic leukaemia: the role of T cells in a B cell disease","volume":"186","author":"Man","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.003_bib0037","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","article-title":"Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine","volume":"106","author":"Beyer","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0038","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"D'Arena","year":"2011","journal-title":"Leuk Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0039","first-page":"157","article-title":"Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type","volume":"49","author":"Herrmann","year":"1982","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.003_bib0040","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/0145-2126(82)90081-9","article-title":"Suppressor t cells in b-cell chronic lymphocytic leukaemia: relationship to clinical stage","volume":"6","author":"Mills","year":"1982","journal-title":"Leukemia Research"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.003_bib0041","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0042","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2014-07-589069","article-title":"Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia","volume":"125","author":"Audrito","year":"2015","journal-title":"Blood"},{"issue":"7519","key":"10.1053\/j.seminhematol.2024.01.003_bib0043","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"issue":"49","key":"10.1053\/j.seminhematol.2024.01.003_bib0044","doi-asserted-by":"crossref","first-page":"84889","DOI":"10.18632\/oncotarget.20031","article-title":"Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects","volume":"8","author":"Manukyan","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.003_bib0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.tips.2021.06.004","article-title":"Targeting natural killer cells to enhance vaccine responses","volume":"42","author":"Cox","year":"2021","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.003_bib0046","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.003_bib0047","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/ni1138","article-title":"Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming","volume":"5","author":"Mart\u00edn-Fontecha","year":"2004","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.003_bib0048","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.celrep.2019.01.104","article-title":"Influenza vaccination Induces NK-cell-mediated type-II IFN response that regulates humoral immunity in an IL-6-dependent manner","volume":"26","author":"Farsakoglu","year":"2019","journal-title":"Cell Rep"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0049","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000203709","article-title":"Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-\u03b1","volume":"96","author":"Katrinakis","year":"1996","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V63.2.305.305","article-title":"Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells","volume":"63","author":"Kay","year":"1984","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0051","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ijc.2910270310","article-title":"Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia","volume":"27","author":"Ziegler","year":"1981","journal-title":"Int J Cancer"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.01.003_bib0052","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.003_bib0053","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.leu.2403083","article-title":"Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy","volume":"17","author":"Guven","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.003_bib0054","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.leukres.2011.02.006","article-title":"Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia","volume":"35","author":"Eskelund","year":"2011","journal-title":"Leukemia Research"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0055","article-title":"Vaccines for the prevention of infections in adults with haematological malignancies","volume":"2023","author":"Hirsch","year":"2023","journal-title":"Cochrane Database Systematic Reviews [Internet]"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.003_bib0056","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41408-022-00776-5","article-title":"Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis","volume":"12","author":"Uaprasert","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.003_bib0057","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1080\/10428194.2022.2092857","article-title":"Monoclonal B-cell lymphocytosis \u2013 a review of diagnostic criteria, biology, natural history, and clinical management","volume":"63","author":"Tang","year":"2022","journal-title":"Leukemia Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0058","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bjh.18014","article-title":"COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity","volume":"197","author":"Shen","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0059","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.26388","article-title":"Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis","volume":"97","author":"Muchtar","year":"2022","journal-title":"American J Hematol"},{"issue":"13\u201314","key":"10.1053\/j.seminhematol.2024.01.003_bib0060","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0264-410X(00)00409-6","article-title":"Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia","volume":"19","author":"Hartkamp","year":"2001","journal-title":"Vaccine"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.01.003_bib0061","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.003_bib0062","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.003_bib0063","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0064","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.2020008758","article-title":"Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines","volume":"137","author":"Pleyer","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.003_bib0065","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bjh.14855","article-title":"Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib","volume":"182","author":"Andrick","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.003_bib0066","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1080\/21645515.2019.1627160","article-title":"Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia","volume":"15","author":"Lindstr\u00f6m","year":"2019","journal-title":"Human Vaccines Immunotherapeutics"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0067","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41375-020-0884-z","article-title":"Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)","volume":"35","author":"Mauro","year":"2021","journal-title":"Leukemia"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.01.003_bib0068","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1016\/j.vaccine.2018.05.012","article-title":"Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia a randomized study by the Swedish CLL group","volume":"36","author":"Svensson","year":"2018","journal-title":"Vaccine"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.003_bib0069","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.3324\/haematol.2017.164285","article-title":"Ibrutinib may impair serological responses to influenza vaccination","volume":"102","author":"Douglas","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.003_bib0070","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1001\/jamaoncol.2016.2437","article-title":"Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.003_bib0071","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0953-6205(01)00149-2","article-title":"Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients","volume":"12","author":"Van Der Velden","year":"2001","journal-title":"Eur J Internal Med"},{"key":"10.1053\/j.seminhematol.2024.01.003_bib0072","series-title":"Viral, parasitic, bacterial, and fungal infections [Internet]","first-page":"699","article-title":"Vaccines: An overview","author":"Lopez","year":"2023"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0073","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.003_bib0074","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004157","article-title":"Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study","volume":"20","author":"Qin","year":"2023","journal-title":"PLoS Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.chom.2019.01.002","article-title":"Influenza Virus vaccination elicits poorly adapted B cell responses in elderly individuals","volume":"25","author":"Henry","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.01.003_bib0076","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1073\/pnas.1118979109","article-title":"Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.003_bib0077","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/bloodadvances.2021006574","article-title":"BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL","volume":"6","author":"Pleyer","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0078","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.003_bib0079","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1586\/erv.12.125","article-title":"Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"71","key":"10.1053\/j.seminhematol.2024.01.003_bib0080","doi-asserted-by":"crossref","first-page":"eabo1303","DOI":"10.1126\/sciimmunol.abo1303","article-title":"Understanding T cell responses to COVID-19 is essential for informing public health strategies","volume":"7","author":"Vardhana","year":"2022","journal-title":"Sci Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0081","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/vaccines6030043","article-title":"Methods for measuring T-cell memory to vaccination: from mouse to man","volume":"6","author":"Flaxman","year":"2018","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.003_bib0082","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.003_bib0083","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41375-020-01074-4","article-title":"Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma","volume":"35","author":"Zent","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.003_bib0084","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1053\/j.seminhematol.2024.01.003_bib0085","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.01.003_bib0086","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood.2022017814","article-title":"Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion","volume":"140","author":"Shen","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.01.003_bib0087","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1016\/S2152-2650(22)01348-9","article-title":"CLL-461 humoral response to COVID-19 vaccine: a challenge in CLL","volume":"22","author":"Capasso","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.003_bib0088","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID -19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.003_bib0089","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/bloodadvances.2021006574","article-title":"BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL","volume":"6","author":"Pleyer","year":"2022","journal-title":"Blood Advances"},{"key":"10.1053\/j.seminhematol.2024.01.003_bib0090","first-page":"1","article-title":"Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL","author":"Tomasulo","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.003_bib0091","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.003_bib0092","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/bloodadvances.2022008221","article-title":"Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells","volume":"7","author":"Teh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.01.003_bib0093","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221090150","article-title":"Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study","volume":"13","author":"Diamantopoulos","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1053\/j.seminhematol.2024.01.003_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101077","article-title":"Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2","volume":"60","author":"Fattizzo","year":"2023","journal-title":"Blood Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/bloodadvances.2021006215","article-title":"Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia","volume":"6","author":"Bagacean","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.003_bib0096","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000514071","article-title":"Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic","volume":"144","author":"Langerbeins","year":"2021","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0097","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"107","author":"Benjamini","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.003_bib0098","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2021014085","article-title":"Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination","volume":"139","author":"Herishanu","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0099","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/blood.2021013445","article-title":"Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients","volume":"139","author":"Liebers","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.003_bib0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3324\/haematol.2010.032664","article-title":"Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host","volume":"96","author":"de Lavallade","year":"2011","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.01.003_bib0101","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212688","article-title":"Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient","author":"Costa","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.003_bib0102","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/vaccines11071201","article-title":"Immunogenicity of the 13-valent pneumococcal conjugated vaccine followed by the 23-valent polysaccharide vaccine in chronic lymphocytic leukemia","volume":"11","author":"Haggenburg","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.003_bib0103","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/10428194.2022.2133538","article-title":"Vaccination efficacy in patients with chronic lymphocytic leukemia","volume":"64","author":"Wang","year":"2023","journal-title":"Leukemia & Lymphoma"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.003_bib0104","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/vaccines10050819","article-title":"An overview of vaccine adjuvants: current evidence and future perspectives","volume":"10","author":"Facciol\u00e0","year":"2022","journal-title":"Vaccines"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.003_bib0105","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/jha2.724","article-title":"Immune response to COVID-19 vaccination in patients with Waldenstr\u00f6m macroglobulinaemia who pause their BTKi therapy","volume":"4","author":"Rankin","year":"2023","journal-title":"EJHaem"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T21:32:20Z","timestamp":1729200740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0037196324000040"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccinations in patients with chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}